(5 references)-
- 抗原 See all SFXN1 抗体
- SFXN1 (Sideroflexin 1 (SFXN1))
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This SFXN1 antibody is conjugated to FITC
-
应用范围
- Functional Studies (Func)
- 交叉反应 （详细）
- Cross reactivity: Horse : Yes, Swine : Yes
- 过滤
- 0.2 μm filtered
- 克隆位点
- AE11
- 亚型
- IgG2a
- Top Product
- Discover our top product SFXN1 Primary Antibody
-
anti-Sideroflexin 1 (SFXN1) (AA 2-102) antibody
SFXN1 适用: 小鼠 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
anti-Sideroflexin 1 (SFXN1) (AA 1-322) antibodySFXN1 适用: 人 WB 宿主: 小鼠 Polyclonal unconjugated
anti-Sideroflexin 1 (SFXN1) (AA 1-186) antibodySFXN1 适用: 人 WB, IHC, IHC (p) 宿主: 兔 Polyclonal unconjugated
anti-Sideroflexin 1 (SFXN1) (N-Term) antibodySFXN1 适用: 人, 小鼠, 大鼠, 兔, Cow, 斑马鱼, 豚鼠, 马, 猴, Pig WB 宿主: 兔 Polyclonal unconjugated
anti-Sideroflexin 1 (SFXN1) (AA 87-322) antibodySFXN1 适用: 人 WB 宿主: 兔 Polyclonal unconjugated
anti-Sideroflexin 1 (SFXN1) (N-Term) antibodySFXN1 适用: 人 WB 宿主: 兔 Polyclonal unconjugated
anti-Sideroflexin 1 (SFXN1) (AA 293-321), (C-Term) antibodySFXN1 适用: 人 WB 宿主: 兔 Polyclonal RB42788 unconjugated
anti-Sideroflexin 1 (SFXN1) (N-Term) antibodySFXN1 适用: 人, 小鼠, 大鼠, 兔, Cow, 斑马鱼, 豚鼠, 马, 绵羊, 犬 WB 宿主: 兔 Polyclonal unconjugated
-
- 应用备注
- For immunohistochemistry and flow cytometry dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. Positive Mucosa from patients with H. Pylori. control 1
- 限制
- 仅限研究用
-
- 缓冲液
- PBS, containing 1.0 % bovine serum albumin and 0.02 % sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C
- 储存方法
- Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
-
-
: "Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction." in: Journal of clinical pathology, Vol. 59, Issue 2, pp. 196-201, (2006) (PubMed).
: "Epithelium related deposition of activated complement in Helicobacter pylori associated gastritis." in: Gut, Vol. 40, Issue 2, pp. 196-203, (1997) (PubMed).
: "Antiphospholipid antibody-dependent C5b-9 formation." in: British journal of haematology, Vol. 96, Issue 3, pp. 451-7, (1997) (PubMed).
: "Human alveolar macrophages synthesize active complement components C6, C7, and C8 in vitro." in: Scandinavian journal of immunology, Vol. 25, Issue 6, pp. 567-70, (1987) (PubMed).
: "Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex." in: Scandinavian journal of immunology, Vol. 22, Issue 2, pp. 197-202, (1985) (PubMed).
-
: "Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction." in: Journal of clinical pathology, Vol. 59, Issue 2, pp. 196-201, (2006) (PubMed).
-
- 抗原
- SFXN1 (Sideroflexin 1 (SFXN1))
- 别名
- Tcc (SFXN1 产品)
- 别名
- zgc:100851 antibody, 2810002O05Rik antibody, A930015P12Rik antibody, f antibody, Sideroflexin 1 antibody, sideroflexin 1 antibody, sideroflexin 1 L homeolog antibody, Bm1_35025 antibody, sfxn1 antibody, sfxn1.L antibody, SFXN1 antibody, Sfxn1 antibody
- 背景
- Monoclonal antibody aE11 reacts with a C9 neoantigen of the terminal complement complex (TCC). The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 Molecules associate with the C5b678 complex, which is also termed the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components. C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation. Aliases MAC, membrane attack complex, sC5b-9 complex
- 途径
- Transition Metal Ion Homeostasis
-
You are here:
